Torrance Clinical Research Institute Inc.
Welcome,         Profile    Billing    Logout  
 7 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Raikhel, Marina
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Enrolling by invitation
3
285
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26
NCT05312567: FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms

Completed
2
105
US
FP-101
Fervent Pharmaceuticals, ICON plc
Vasomotor Symptoms, Menopause
04/23
07/23
NEPTUNE-17, NCT05838755: A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain

Active, not recruiting
2
145
Europe, Canada, Japan, US, RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain
10/24
01/25
NCT05138822: Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections

Completed
1
140
US
GSK3882347, Nitrofurantoin, Placebo
GlaxoSmithKline
Uncomplicated Urinary Tract Infections, Urinary Tract Infections
12/24
12/24
Costa, Evelyn F
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting
2
288
US
CIN-102 Dose 15mg or 10mg, Placebo
CinDome Pharma, Inc.
Diabetic Gastroparesis
09/25
09/25
Johnson
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
NCT06057012: A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)

Completed
2
11
US
BRII-296, Depo Medrol
Brii Biosciences Limited
Severe Postpartum Depression
03/24
03/24
ETC, NCT05225740: Exposure Therapy Consortium () for Anxiety Sensitivity

Active, not recruiting
N/A
399
Europe, US, RoW
Standard Exposure, Stress Management Training, Enhanced Exposure
University of Texas at Austin, University of North Carolina, Chapel Hill, University of Colorado, Boulder, University of Miami, University of Mississippi, Oxford, Ruhr University of Bochum, Boston University, Fordham University, The University of New South Wales, Southern Methodist University, Institute of Behavioral-Therapy and -Medicine at the Philipps University Marburg, Technische Universität Dresden, Curtin University, Hebrew University of Jerusalem, University of Göttingen
Elevated Anxiety Sensitivity
09/24
09/24
NCT01522183: Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Recruiting
N/A
3000
Europe, Canada, US, RoW
Alexion Pharmaceuticals, Inc., Syneos Health
Atypical Hemolytic-Uremic Syndrome
01/31
01/31
NCT02103361: Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project

Recruiting
N/A
200
US
Ustekinumab, Stelara, Guselkumab, Tremfya
University of California, San Diego, The Organization of Teratology Information Specialists, Janssen Biotech, Inc.
Psoriasis, Pregnancy, Psoriatic Arthritis, Crohn Disease
05/30
02/31
Musil, Caitlynn
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting
2
288
US
CIN-102 Dose 15mg or 10mg, Placebo
CinDome Pharma, Inc.
Diabetic Gastroparesis
09/25
09/25
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
Raikhel
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
Morales, Eugene
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting
2
288
US
CIN-102 Dose 15mg or 10mg, Placebo
CinDome Pharma, Inc.
Diabetic Gastroparesis
09/25
09/25
Arsate, Mariam
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting
2
288
US
CIN-102 Dose 15mg or 10mg, Placebo
CinDome Pharma, Inc.
Diabetic Gastroparesis
09/25
09/25

Download Options